Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies

Objective: To assess the importance of MAPT variant p.A152T in the risk of synucleinopathies. Methods: In this case-control study, we screened a large global series of patients and controls, and assessed associations between p.A152T and disease risk. We included 3,229 patients with clinical Parkinson disease (PD), 442 with clinical dementia with Lewy bodies (DLB), 181 with multiple system atrophy (MSA), 832 with pathologically confirmed Lewy body disease (LBD), and 2,456 healthy controls. Results: The minor allele frequencies (MAF) in clinical PD cases (0.28%) and in controls (0.2%) were not found to be significantly different (odds ratio [OR] 1.37, 95% confidence interval [CI] 0.63–2.98, p = 0.42). However, a significant association was observed with clinical DLB (MAF 0.68%, OR 5.76, 95% CI 1.62–20.51, p = 0.007) and LBD (MAF 0.42%, OR 3.55, 95% CI 1.04–12.17, p = 0.04). Additionally, p.A152T was more common in patients with MSA compared to controls (MAF 0.55%, OR 4.68, 95% CI 0.85–25.72, p = 0.08) but this was not statistically significant and therefore should be interpreted with caution. Conclusions: Overall, our findings suggest that MAPT p.A152T is a rare low penetrance variant likely associated with DLB that may be influenced by coexisting LBD and AD pathology. Given the rare nature of the variant, further studies with greater sample size are warranted and will help to fully explain the role of p.A152T in the pathogenesis of the synucleinopathies.

[1]  Elisabeth L. Moussaud-Lamodière,et al.  Alpha-synuclein and tau: teammates in neurodegeneration? , 2014, Molecular Neurodegeneration.

[2]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[3]  W. M. van der Flier,et al.  Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies , 2014, Human molecular genetics.

[4]  Yoav Ben-Shlomo,et al.  Parkinson’s Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis , 2014, Journal of Parkinson's disease.

[5]  R. Uitti,et al.  Investigating the role of FUS exonic variants in essential tremor. , 2013, Parkinsonism & related disorders.

[6]  J. Hardy,et al.  The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features , 2012, Neurobiology of Aging.

[7]  J. Ioannidis,et al.  Large-scale replication and heterogeneity in Parkinson disease genetic loci , 2012, Neurology.

[8]  Michelle K. Lupton,et al.  Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. , 2012, Human molecular genetics.

[9]  Chuong B. Do,et al.  Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.

[10]  M. Farrer,et al.  MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy , 2011, Neurology.

[11]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[12]  G. Muntané,et al.  Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related α-synucleinopathies , 2008, Neuroscience.

[13]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[14]  H. Fung,et al.  Untangling the tau gene association with neurodegenerative disorders. , 2006, Human molecular genetics.

[15]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[16]  M. Farrer,et al.  Linkage disequilibrium and association of MAPT H1 in Parkinson disease. , 2004, American journal of human genetics.

[17]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[18]  J. Trojanowski,et al.  Concurrence of α-synuclein and tau brain pathology in the Contursi kindred , 2002, Acta Neuropathologica.

[19]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[20]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[21]  G. Halliday,et al.  α-Synucleinopathy phenotypes. , 2014, Parkinsonism & related disorders.

[22]  J. Attems,et al.  Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7. , 2011, Clinical neuropathology.

[23]  G. Muntané,et al.  2.319 Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's Disease, and in Parkinson's disease and related alpha-synucleinopathies , 2007 .

[24]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[25]  J. Trojanowski,et al.  Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. , 2002, Acta neuropathologica.

[26]  K. Jellinger,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.